UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics

Barbieri, CE; Chinnaiyan, AM; Lerner, SP; Swanton, C; Rubin, MA; (2017) The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology , 71 (2) pp. 237-246. 10.1016/j.eururo.2016.08.024. Green open access

[img]
Preview
Text
nihms-812684.pdf - Accepted version

Download (601kB) | Preview

Abstract

CONTEXT: Biomarker-driven cancer therapy, also referred to as precision oncology, has received increasing attention for its promise of improving patient outcomes by defining subsets of patients more likely to respond to various therapies. OBJECTIVES: In this collaborative review article, we examine recent literature regarding biomarker-driven therapeutics in urologic oncology, to better define the state of the field, explore the current evidence supporting utility of this approach, and gauge potential for the future. EVIDENCE ACQUISITION: We reviewed relevant literature, with a particular focus on recent studies about targeted therapy, predictors of response, and biomarker development. EVIDENCE SYNTHESIS: The recent advances in molecular profiling have led to a rapid expansion of potential biomarkers and predictive information for patients with urologic malignancies. Across disease states, distinct molecular subtypes of cancers have been identified, with the potential to inform choices of management strategy. Biomarkers predicting response to standard therapies (such as platinum-based chemotherapy) are emerging. In several malignancies (particularly renal cell carcinoma and castration-resistant prostate cancer), targeted therapy against commonly altered signaling pathways has emerged as standard of care. Finally, targeted therapy against alterations present in rare patients (less than 2%) across diseases has the potential to drastically alter patterns of care and choices of therapeutic options. CONCLUSIONS: Precision medicine has the highest potential to impact the care of patients. Prospective studies in the setting of clinical trials and standard of care therapy will help define reliable predictive biomarkers and new therapeutic targets leading to real improvement in patient outcomes. PATIENT SUMMARY: Precision oncology uses molecular information (DNA and RNA) from the individual and the tumor to match the right patient with the right treatment. Tremendous strides have been made in defining the molecular underpinnings of urologic malignancies and understanding how these predict response to treatment—this represents the future of urologic oncology.

Type: Article
Title: The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.eururo.2016.08.024
Publisher version: https://doi.org/j.eururo.2016.08.024
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Precision Medicine, Mutations, Sequencing, Genomics
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10055866
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item